Injectable mRNA immunotherapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new type of immunotherapy that is injected directly into a tumor. The treatment uses mRNA (genetic material) wrapped in a fat particle to stimulate your immune system to attack the cancer. It's for people with advanced solid tumors that haven't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a solid tumor cancer (not a blood cancer) that is advanced or has spread, and has not improved with standard treatments.
- Your tumor must have a protein called EpCAM on at least half of its cells. The test for this is done in a central lab.
- You must have at least one tumor that is 2 cm or larger (about the size of a grape) and can be safely reached with a needle for injection.
- You should be in generally good health — able to do light work or be fully active (ECOG 0–1).
- You must have adequate organ function (blood counts, liver, kidneys, and blood clotting) and be willing to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
This trial tests a personalized mRNA vaccine (InnoPCV) designed from your own tumor's genetic profile to train your immune system to fight advanced solid tumors. It is for people who have not had tumor vaccines or CAR-T therapy before and can provide a tumor sample for customized vaccine creation.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial tests a new inhaled mRNA therapy that may help your immune system fight cancer. It is for people with advanced lung cancer or cancer that has spread to the lungs when standard treatments have stopped working.
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
This trial tests a personalized mRNA vaccine made from your tumor's unique markers (neoantigens) to train your immune system to fight cancer. It is for people with advanced solid tumors who have not had gene therapy and are healthy enough for the vaccine.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.